Companies
PharmaMar
a marine natural-products drug developer advancing clinical candidates including PM534 and PM742, which announced an AI collaboration with Globant in March 2026 aimed at accelerating oncology research with claimed 15x-faster insight generation and over 90% accuracy in its agentic research workflow.
- Country
- Spain
Commercial
Marine natural-product oncology pipeline (PM534, PM742); AI collaboration with Globant, Mar 2026
eu
Coverage
| CN | EU | US | |
|---|---|---|---|
| marine-biotech | ✓ | ✓ | ✓ |
Regulatorsun-doalosepa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Founded | 1986 | marketscreener.com |
| Revenue | €221.39 million (FY 2025) | pharmamar.com · marketscreener.com |
| Headcount | 518 employees (as of end of 2025) | marketscreener.com |
| Production site | Getafe, Madrid (oligonucleotide plant) | pharmamar.com |
| Certification | Good Manufacturing Practices (GMP) certification for oligonucleotide plant in Getafe (EMA/AEMPS) | pharmamar.com |
| Regulatory approval | FDA approval for Zepzelca in combination with Tecentriq (US, Oct 2025) | pharmamar.com |
| Regulatory approval | Positive opinion from EMA recommending Zepzelca in combination with atezolizumab (EU, March 2026) | pharmamar.com |
| Capacity | 3,800 m2 of production warehouse in Madrid designed for GMP standards medium confidence | conferenceharvester.com |
Independent sources: conferenceharvester.com · marketscreener.com
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Marine genomic prospecting & the BBNJ treaty | marine-biotech | Medium | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.